scholarly article | Q13442814 |
P2093 | author name string | Lo KW | |
Johnson PJ | |||
Chan AT | |||
Huang DP | |||
Leung SF | |||
Lo YM | |||
Chan LY | |||
P433 | issue | 9 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | adaptive radiation therapy | Q180507 |
Epstein–Barr virus | Q6900 | ||
P304 | page(s) | 2351-2355 | |
P577 | publication date | 2000-05-01 | |
P1433 | published in | Cancer Research | Q326097 |
P1476 | title | Kinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma | |
P478 | volume | 60 |
Q35121627 | A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer |
Q37175573 | Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial. |
Q59350023 | Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742) |
Q47136367 | Cell-Free DNA Kinetics in a Pre-Clinical Model of Head and Neck Cancer |
Q46670174 | Cell-free circulating tumor DNA analysis for breast cancer and its clinical utilization as a biomarker |
Q26750899 | Cell-free circulating tumor DNA in cancer |
Q93105377 | Clinical value of a plasma Epstein-Barr virus DNA assay in the diagnosis of recurrent or metastatic nasopharyngeal carcinoma: a meta-analysis |
Q37325545 | Clinical values of multiple Epstein-Barr virus (EBV) serological biomarkers detected by xMAP technology |
Q40042999 | Combination of Tumor Volume and Epstein-Barr Virus DNA Improved Prognostic Stratification of Stage II Nasopharyngeal Carcinoma in the IMRT Era: A Large-Scale Cohort Study |
Q90075625 | Combining pretreatment plasma Epstein-Barr virus DNA level and cervical node necrosis improves prognostic stratification in patients with nasopharyngeal carcinoma: A cohort study |
Q33764579 | Current management strategy of nasopharyngeal carcinoma. |
Q64899007 | Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA). |
Q52679757 | Dynamic changes in plasma Epstein-Barr virus DNA load during treatment have prognostic value in nasopharyngeal carcinoma: a retrospective study. |
Q45590622 | Evaluation of epstein-barr virus DNA load in gastric mucosa with chronic atrophic gastritis using a real-time quantitative PCR assay |
Q90664639 | Head and Neck Squamous Cell Carcinoma Detection and Surveillance: Advances of Liquid Biomarkers |
Q35087399 | Impact of plasma Epstein-Barr virus-DNA and tumor volume on prognosis of locally advanced nasopharyngeal carcinoma |
Q37192117 | Laboratory assays for Epstein-Barr virus-related disease |
Q36335515 | Levels of plasma Epstein-Barr virus DNA prior and subsequent to treatment predicts the prognosis of nasopharyngeal carcinoma |
Q38385856 | Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079). |
Q21093175 | Nasopharyngeal carcinoma |
Q92073973 | PD-L1 Expression on Tumor Cells Is Associated With a Poor Outcome in a Cohort of Caucasian Nasopharyngeal Carcinoma Patients |
Q59382383 | Phase I Trial of Recombinant Modified Vaccinia Ankara Encoding Epstein-Barr Viral Tumor Antigens in Nasopharyngeal Carcinoma Patients |
Q34520470 | Phase I clinical trial of valacyclovir and standard of care cyclophosphamide in children with endemic Burkitt lymphoma in Malawi |
Q55234264 | Plasma Cell-Free DNA as a Predictive Marker after Radiotherapy for Hepatocellular Carcinoma. |
Q38270678 | Plasma Epstein-Barr virus DNA as a biomarker for nasopharyngeal carcinoma |
Q36305182 | Positivity of both plasma Epstein-Barr virus DNA and serum Epstein-Barr virus capsid specific immunoglobulin A is a better prognostic biomarker for nasopharyngeal carcinoma |
Q36073981 | Predicting Radiotherapy Responses and Treatment Outcomes Through Analysis of Circulating Tumor DNA. |
Q90296660 | Prognostic Value of Plasma EBV DNA for Nasopharyngeal Cancer Patients during Treatment with Intensity-modulated Radiation Therapy and Concurrent Chemotherapy |
Q99711993 | Prognostication of Half-Life Clearance of Plasma EBV DNA in Previously Untreated Non-metastatic Nasopharyngeal Carcinoma Treated With Radical Intensity-Modulated Radiation Therapy |
Q52647899 | Prospective evaluation of plasma Epstein-Barr virus DNA clearance and fluorodeoxyglucose positron emission scan in assessing early response to chemotherapy in patients with advanced or recurrent nasopharyngeal carcinoma. |
Q58093740 | Relationship between pretreatment concentration of plasma Epstein-Barr virus DNA and tumor burden in nasopharyngeal carcinoma: An updated interpretation |
Q36962686 | Risk stratification based on change in plasma Epstein-Barr virus DNA load after treatment in nasopharyngeal carcinoma |
Q33836183 | Sensitive detection of human papillomavirus in cervical, head/neck, and schistosomiasis-associated bladder malignancies |
Q36892139 | The Epstein Barr virus DNA levels as a tumor marker in EBV-associated cancers. |
Q36152889 | The clinical utility of plasma Epstein-Barr virus DNA assays in nasopharyngeal carcinoma: the dawn of a new era?: a systematic review and meta-analysis of 7836 cases |
Search more.